News

Zongertinib shows early symptom relief in LUNG-1 PRO trial, with physical functioning improvements appearing within one week of first-line...

Aktis Oncology reports lower salivary gland toxicity for AKY-2519 compared to approved PSMA-targeted radiopharmaceuticals in prostate cancer.

TaiMed completes Phase 2b enrollment for TMB-365/380, an HIV therapy candidate designed to eliminate pre-treatment susceptibility screening requirements.

Infex's RESP-X showed reduced exacerbation rates in non-cystic fibrosis bronchiectasis patients colonized with Pseudomonas aeruginosa in Phase IIa data.

Tedopi Plus Pembrolizumab met its primary endpoint in the TEDOVA trial, reducing progression or death risk by 47% in...

BIIB122 failed to slow Parkinson's progression in a Phase 3 trial despite achieving over 90% target engagement in 648...

Infex RESP-X shows safety, reduces exacerbations in bronchiectasis trial. Quarterly dosing monoclonal targets pseudomonas virulence.

TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 HIV therapy, a dual antibody combination dosed every two months without...

Nuvalent neladalkib achieves oral presentation at 2026 ASCO for ALK-positive NSCLC, with NDA filed in April ahead of FDA...

Sapience's lucicebtide demonstrated 28.4-month median progression-free survival in newly diagnosed glioblastoma, significantly exceeding historical benchmarks i